Page 87 - Read Online

mechanism of action. Endocrinology 1992;130:1816-21. Olsson L, Fjälling M, Forssell-Aronsson E, Ahlman H. Comparative
15. Hoyer D, Bell GI, Berelowitz M, Epelbuam J, Feniuk W, Humphrey studies on the expression of somatostatin receptor subtypes, outcome
PP, O’Carroll AM, Patel YC, Schnbrunn A, Taylor JE. Classification of octreotide scintigraphy and response to octreotide treatment in
and nomenclature of somatostatin receptor. Trends Pharmacol Sci patients with carcinoid tumours. Br J Cancer 1998;77:632-7.
1995;16:86-8. 30. Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau
16. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach JW, Reading CC, Moertel C. Detection of somatostatin receptors in
P, Petcher TJ, Pless. SMS 201-995: a very potent and selective surgical and percutaneous needle biopsy samples of carcinoids and
octapeptide analogue of somatostatin with prolonged action. Life islet cell carcinomas. Cancer Res 1990;50:5969-77.
Sci 1982;31:1133-40. 31. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij
17. Bruns C, Weckbecker G, Raulf F, Kaupmann K, Schoeffter P, Hoyer PP, Oei Hy, van Hagen M, Postema PT, de Jong M, Reubi JC.
D, Lübbert H. Molecular pharmacology of somatostatin-receptor Somatostatin receptor scintigraphy with 111In-STPA-D-Phe1 and
subtyes. Ann N Y Acad Sci 1994;733:138-46. 123-Tyr3-octreotide the Rotterdam experience with more than 1000
18. Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, patients. Eur J Nucl Med 1993;20:716-31.
Wiseman GA, Kvols LK; North American Neuroendocrine 32. Panzuto F, Capurso G, Delle Fave G. Medical treatment of gastro-
Tumor Society (NANETS). The NANETS consensus guidelines entero-pancreatic endocrine tumours. In: Modlin IM, Oberg K. A
for the diagnosis and management of poorly differentiated (high- century of advences in neuroendocrine tumor biology and treatment.
grade) extrapulmonary neuroendocrine carcinomas. Pancreas Published by Felsenstein CCC; 2007. p. 364-9.
2010;39:799-800. 33. Strosberg JR, Fisher GA, Benson AB, Malin JL, GEPNET
19. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund Treatment Consensus Panel, Cherepanov D, Broder MS, Anthony
P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, LB, Arslan B, Fisher GA, Gibbs JF, Greeno E, Iyer RV, Kim MK,
Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Maples W, Philip PA, Strosberg J, Wolin EM. Systemic treatment
Federspiel B, Assmus J, Janson ET, Knigge U. Predictive and in unresectable metastatic well-differentiated carcinoid tumors:
prognostic factors for treatment and survival in 305 patients with consensus results from a modified delphi process. Pancreas
advanced gastrointestinal poorly differentiated neuroendocrine 2013;42:397-404.
carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 34. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P,
2013;24:152-60. Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder
20. Walter T, Bruneton D, Cassier PA, Hervieu V, Pilleul F, Scoazec JY, J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-
Chayvialle JA, Lombard-Bohas C. Evaluation of the combination controlled, double-blind, prospective, randomized study on the
5-fluorouracil, dacarbazine, and epirubicin in patients with advanced effect of octreotide LAR in the control of tumor growth in patients
well-differentiated neuroendocrine tumors. Clin Colorectal Cancer with metastatic neuroendocrine midgut tumours: a report from the
2010;9:248-54. PROMID study Group. J Clin Oncol 2009;27:4565-63.
21. Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan 35. Janson ET, Oberg K. Long-term management of the carcinoid
DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, syndrome. Treatment with octreotide alone and in combination with
Redston MS. O6-methylguanine DNA methyltransferase deficiency alpha-interferon. Acta Oncol 1993;32:225-9.
and response to temozolomide-based therapy in patients with 36. Kvols LK, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn
neuroendocrine tumors. Clin Cancer Res 2009;15:338-45. RG. Treatment of the malignant carcinoid syndrome. Evaluation of
22. Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari a long-acting somatostatin analogue. N Engl J Med 1986;315:663-6.
L, Martinetti A, Platania M, Verzoni E, Formisano B, Bajetta R. 37. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier
Are capecitabine and oxaliplatin (XELOX) suitable treatments for R, Saltz L, Dandona P, Anthony L. Octreotide acetate long-acting
progressing low-grade and high-grade neuroendocrine tumours? formulation versus open-label subcutaneous octreotide acetate in
Cancer Chemother Pharmacol 2007;59:637-42. malignant carcinoid syndrome. J Clin Oncol 1999:17:600-6.
23. Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, 38. Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B,
Tozzi L, Bodei L, Torta M, D’Avolio A, Priola AM, Birocco N, Ronicke E, Gress TM, Müller HH, Arnold R; PROMID Study
Amoroso V, Biasco G, Papotti M, Dogliotti L. Bevacizumab plus Group. Placebo controlled, double blind, prospective, randomized
octreotide and metronomic capecitabine in patients with metastatic study on the effect of octreotide LAR in the control of tumor
well-to-moderately differentiated neuroendocrine tumors: the growth in patients with metastatic neuroendocrine midgut tumors
XELBEVOCT study. BMC Cancer 2014;14:184. (PROMID): Results on long-term survival (abstract). ASCO
24. Koumarianou A, Antoniou S, Kanakis G, Economopoulos meeting Abstracts 2013;31:4030.
N, Rontogianni D, Ntavatzikos A, Tsavaris N, Pectasides D, 39. Sandostatin LAR Depot [prescribing information]. East Hanover,
Dimitriadis G, Kaltsas G. Combination treatment with metronomic New Jersey: Novartis Pharmaceuticals Corporation; 2011. [cited
temozolomide, bevacizumab and long-acting octreotide for 2014 Jul 30] Available from: http://www.accessdata.fda.gov/
malignant neuroendocrine tumours. Endocr Relat Cancer scripts/cder/drugsatfda/.
2012;19:L1-4. 40. Khan MS, El-Khouly F, Davies P, Toumpanakis C, Caplin ME.
25. Brazeau P, Vale W, Burgus E, Ling N, Butcher M, Rivier J, Long-term results of treatment of malignant carcinoid syndrome
Guillemin R. Hypothalamic polypeptide that inhibits the secretion of with prolonged release Lanreotide (Somatuline Autogel). Aliment
immunoreactive pituitary growth hormone. Science 1973;179:77-9. Pharmacol Ther 2011;34:235-42.
26. Burgus R, Ling N, Butcher M, Guillemin R. Primary structure of 41. O’Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouché
somatostatin, a hypotalamic peptide that inhibits the secretion of O, Catus F, Blumberg J, Ruszniewski P. Treatment of carcinoid
pituitary growth hormone. Proc Natl Acad Sci U S A 1973;70:684-8. syndrome: a prospective crossover evaluation of lanreotide versus
27. Reisine T, Bell GI. Molecular biology of somatostatin receptors. octreotide in terms of efficacy, patient acceptability, and tolerance.
Endocr Rev 1995;16: 427-42. Cancer 2000;88:770-6.
28. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning 42. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem
and functional characterization of a family of human and mouse EJ, Fiasse RH, Välimäki MJ, Renstrup J, de Vries EG, Oberg KE.
somatostatin receptors expressed in brain, gastrointestinal tract, and Efficacy and safety of prolonged-release lanreotide in patients
kidney. Proc Natl Acad Sci U S A 1992;89:251-5. with gastrointestinal neuroendocrine tumors and hrmone-related
29. Nilsson O, Kölby L, Wängberg B, Wigander A, Billig H, William- symptoms. J Clin Oncol 1999;17:1111.
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 31, 2016 ¦ 319